REQUEST A DEMO
Total
USD $0.00
Search more companies

Farmasol Tibbi Urunler A.S. (Turkiye)

Main Activities: Surgical and Medical Instrument Manufacturing
Full name: Farmasol Tibbi Urunler Sanayi Ve Ticaret Anonim Sirketi Profile Updated: August 01, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Farmasol Tibbi Urunler A.S. is an enterprise located in Turkiye, with the main office in Kayseri. The enterprise operates in the Surgical and Medical Instrument Manufacturing industry. The company was established on February 12, 2004. 130 (2024) employees currently work for Farmasol Tibbi Urunler A.S.. There was a net sales revenue increase of 67.08% reported in Farmasol Tibbi Urunler A.S.’s latest financial highlights for 2023. Its’ total assets recorded a growth of 177.58%. The net profit margin of Farmasol Tibbi Urunler A.S. increased by 5.29% in 2023.

Headquarters
No:7 Organize Sanay Bolgesi 18.caddesi Melikgazi
Kayseri; Central Anatolia; Postal Code: 38070

Contact Details: Purchase the Farmasol Tibbi Urunler A.S. report to view the information.

Website: http://www.farmasol.com.tr

Basic Information
Total Employees:
Purchase the Farmasol Tibbi Urunler A.S. report to view the information.
Outstanding Shares:
Purchase the Farmasol Tibbi Urunler A.S. report to view the information.
Incorporation Date:
February 12, 2004
Key Executives
Purchase this report to view the information.
Chairman
Company Performance
Financial values in the chart are available after Farmasol Tibbi Urunler A.S. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TRY. Absolute financial data is included in the purchased report.
Net sales revenue
67.08%
Total operating revenue
67.08%
Operating profit (EBIT)
215.5%
Net Profit (Loss) for the Period
168.95%
Total assets
177.58%
Total equity
195.82%
Operating Profit Margin (ROS)
6.9%
Net Profit Margin
5.29%
Return on Equity (ROE)
-2.84%
Debt to Equity Ratio
-10.63%
Quick Ratio
-0.41%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?